Nrf2: a potential therapeutic target for naturally occurring anticancer drugs?

References

• Hayes JD, McMahon M. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci. 2009;34:176–188.
   PubMed Web of Science ®Google Scholar
• Dinkova-Kostova AT, Kazantsev AG. Activation of Nrf2 signaling as a common treatment of neurodegenerative diseases. Neurodegener Dis Manag. 2017;7:97–100.
   PubMed Web of Science ®Google Scholar
• Taguchi K, Motohashi H, Yamamoto M. Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells. 2011;16:123–140.
   PubMed Web of Science ®Google Scholar
• Zhu J, Wang H, Chen F, et al. An overview of chemical inhibitors of the Nrf2-ARE signaling pathway and their potential applications in cancer therapy. Free Radic Biol Med. 2016;99:544–556.
   PubMed Web of Science ®Google Scholar
• Taguchi K, Fujikawa N, Komatsu M, et al. Keap1 degradation by autophagy for the maintenance of redox homeostasis. Proc Natl Acad Sci U S A. 2012;109:13561–13566.
   PubMed Web of Science ®Google Scholar
• Krajka-Kuźniak V, Paluszczak J, Baer-Dubowska W. The Nrf2-ARE signaling pathway: an update on its regulation and possible role in cancer prevention and treatment. Pharmacol Rep. 2016;69:393–402.
   PubMedGoogle Scholar
• Sun Z, Zhang S, Chan JY, et al. Keap1 controls postinduction repression of the Nrf2-mediated antioxidant response by escorting nuclear export of Nrf2. Mol Cell Biol. 2007;27:6334–6349.
   PubMed Web of Science ®Google Scholar
• Lu MC, Ji JA, Jiang ZY, et al. The Keap1-Nrf2-ARE pathway as a potential preventive and therapeutic target: an update. Med Res Rev. 2016;36:924–963.
   PubMed Web of Science ®Google Scholar
• Xiang M, Namani A, Wu S, et al. Nrf2: bane or blessing in cancer? J Cancer Res Clin Oncol. 2014;140:1251–1259.
   PubMed Web of Science ®Google Scholar
• Lau A, Wang XJ, Zhao F, et al. A noncanonical mechanism of Nrf2 activation by autophagy deficiency: direct interaction between Keap1 and p62. Mol Cell Biol. 2010;30:3275–3285.
   PubMed Web of Science ®Google Scholar
• Khor TO, Fuentes F, Shu L, et al. Epigenetic DNA methylation of antioxidative stress regulator NRF2 in human prostate cancer. Cancer Prev Res (Phila). 2014;7:1186–1197.
   PubMed Web of Science ®Google Scholar
• Muscarella LA, Parrella P, D’Alessandro V, et al. Frequent epigenetics inactivation of KEAP1 gene in non-small cell lung cancer. Epigenetics. 2011;6:710–719.
   PubMed Web of Science ®Google Scholar
• Kensler TW, Wakabayashi N. Nrf2: friend or foe for chemoprevention? Carcinogenesis. 2010;31:90–99.
   PubMed Web of Science ®Google Scholar
• Kansanen E, Kuosmanen SM, Leinonen H, et al. The Keap1-Nrf2 pathway: mechanisms of activation and dysregulation in cancer. Redox Biol. 2013;1:45–49.
   PubMed Web of Science ®Google Scholar
• Ganan-Gomez I, Wei Y, Yang H, et al. Oncogenic functions of the transcription factor Nrf2. Free Radic Biol Med. 2013;65:750–764.
   PubMed Web of Science ®Google Scholar
• Niture SK, Jaiswal AK. Nrf2-induced antiapoptotic Bcl-xL protein enhances cell survival and drug resistance. Free Radic Biol Med. 2013;57:119–131.
   PubMed Web of Science ®Google Scholar
• Yamadori T, Ishii Y, Homma S, et al. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers. Oncogene. 2012;31:4768–4777.
   PubMed Web of Science ®Google Scholar
• Ji X, Wang H, Zhu J, et al. Knockdown of Nrf2 suppresses glioblastoma angiogenesis by inhibiting hypoxia-induced activation of HIF-1alpha. Int J Cancer. 2014;135:574–584.
   PubMed Web of Science ®Google Scholar
• Kim TH, Hur EG, Kang SJ, et al. NRF2 blockade suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation of HIF-1alpha. Cancer Res. 2011;71:2260–2275.
   PubMed Web of Science ®Google Scholar
• Cho JM, Manandhar S, Lee HR, et al. Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance. Cancer Lett. 2008;260:96–108.
   PubMed Web of Science ®Google Scholar
• Bao LJ, Jaramillo MC, Zhang ZB, et al. Nrf2 induces cisplatin resistance through activation of autophagy in ovarian carcinoma. Int J Clin Exp Pathol. 2014;7:1502–1513.
   PubMed Web of Science ®Google Scholar
• Wu KC, Cui JY, Klaassen CD. Effect of graded Nrf2 activation on phase-I and -II drug metabolizing enzymes and transporters in mouse liver. PLoS One. 2012;7:e39006.
   PubMed Web of Science ®Google Scholar
• Marada VV, Florl S, Kuhne A, et al. Interaction of human organic anion transporter 2 (OAT2) and sodium taurocholate cotransporting polypeptide (NTCP) with antineoplastic drugs. Pharmacol Res. 2015;91:78–87.
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2:48–58.
   PubMed Web of Science ®Google Scholar
• Wang X, Campos CR, Peart JC, et al. Nrf2 upregulates ATP binding cassette transporter expression and activity at the blood-brain and blood-spinal cord barriers. J Neurosci. 2014;34:8585–8593.
   PubMed Web of Science ®Google Scholar
• Bao L, Wu J, Dodson M, et al. ABCF2, an Nrf2 target gene, contributes to cisplatin resistance in ovarian cancer cells. Mol Carcinog. 2017;56:1543–1553.
   PubMed Web of Science ®Google Scholar
• Xia C, Bai X, Hou X, et al. Cryptotanshinone reverses cisplatin resistance of human lung carcinoma A549 cells through down-regulating Nrf2 pathway. Cell Physiol Biochem. 2015;37:816–824.
   PubMed Web of Science ®Google Scholar
• Menegon S, Columbano A, Giordano S. The dual roles of NRF2 in cancer. Trends Mol Med. 2016;22:578–593.
   PubMed Web of Science ®Google Scholar
• Gruosso T, Mieulet V, Cardon M, et al. Chronic oxidative stress promotes H2AX protein degradation and enhances chemosensitivity in breast cancer patients. EMBO Mol Med. 2016;8:527–549.
   PubMed Web of Science ®Google Scholar
• Wang XJ, Li Y, Luo L, et al. Oxaliplatin activates the Keap1/Nrf2 antioxidant system conferring protection against the cytotoxicity of anticancer drugs. Free Radic Biol Med. 2014;70:68–77.
   PubMed Web of Science ®Google Scholar
• Furfaro AL, Piras S, Domenicotti C, et al. Role of Nrf2, HO-1 and GSH in neuroblastoma cell resistance to bortezomib. PLoS One. 2016;11:e0152465.
   PubMed Web of Science ®Google Scholar
• Amin AR, Kucuk O, Khuri FR, et al. Perspectives for cancer prevention with natural compounds. J Clin Oncol. 2009;27:2712–2725.
   PubMed Web of Science ®Google Scholar
• Yang L, Palliyaguru DL, Kensler TW. Frugal chemoprevention: targeting Nrf2 with foods rich in sulforaphane. Semin Oncol. 2016;43:146–153.
   PubMed Web of Science ®Google Scholar
• Houghton CA, Fassett RG, Coombes JS. Sulforaphane and other nutrigenomic Nrf2 activators: can the clinician’s expectation be matched by the reality? Oxid Med Cell Longev. 2016;2016:1–17.
   Web of Science ®Google Scholar
• Su ZY, Zhang C, Lee JH, et al. Requirement and epigenetics reprogramming of Nrf2 in suppression of tumor promoter TPA-induced mouse skin cell transformation by sulforaphane. Cancer Prev Res (Phila). 2014;7:319–329.
   PubMed Web of Science ®Google Scholar
• Lubelska K, Wiktorska K, Mielczarek L, et al. Sulforaphane regulates NFE2L2/Nrf2-dependent xenobiotic metabolism phase II and phase III enzymes differently in human colorectal cancer and untransformed epithelial colon cells. Nutr Cancer. 2016;68:1338–1348.
   PubMed Web of Science ®Google Scholar
• Liu M, Yao XD, Li W, et al. Nrf2 sensitizes prostate cancer cells to radiation via decreasing basal ROS levels. Biofactors. 2015;41:52–57.
   PubMed Web of Science ®Google Scholar
• Fahey JW, Haristoy X, Dolan PM, et al. Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors. Proc Natl Acad Sci U S A. 2002;99:7610–7615.
   PubMed Web of Science ®Google Scholar
• Morimitsu Y, Nakagawa Y, Hayashi K, et al. A sulforaphane analogue that potently activates the Nrf2-dependent detoxification pathway. J Biol Chem. 2002;277:3456–3463.
   PubMed Web of Science ®Google Scholar
• Thimmulappa RK, Mai KH, Srisuma S, et al. Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res. 2002;62:5196–5203.
   PubMed Web of Science ®Google Scholar
• Cornblatt BS, Ye L, Dinkova-Kostova AT, et al. Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast. Carcinogenesis. 2007;28:1485–1490.
   PubMed Web of Science ®Google Scholar
• Dickinson SE, Melton TF, Olson ER, et al. Inhibition of activator protein-1 by sulforaphane involves interaction with cysteine in the cFos DNA-binding domain: implications for chemoprevention of UVB-induced skin cancer. Cancer Res. 2009;69:7103–7110.
   PubMed Web of Science ®Google Scholar
• Dinkova-Kostova AT, Jenkins SN, Fahey JW, et al. Protection against UV-light-induced skin carcinogenesis in SKH-1 high-risk mice by sulforaphane-containing broccoli sprout extracts. Cancer Lett. 2006;240:243–252.
   PubMed Web of Science ®Google Scholar
• Hong F, Freeman ML, Liebler DC. Identification of sensor cysteines in human Keap1 modified by the cancer chemopreventive agent sulforaphane. Chem Res Toxicol. 2005;18:1917–1926.
   PubMed Web of Science ®Google Scholar
• Gills JJ, Jeffery EH, Matusheski NV, et al. Sulforaphane prevents mouse skin tumorigenesis during the stage of promotion. Cancer Lett. 2006;236:72–79.
   PubMed Web of Science ®Google Scholar
• Xu C, Huang MT, Shen G, et al. Inhibition of 7,12-dimethylbenz(a)anthracene-induced skin tumorigenesis in C57BL/6 mice by sulforaphane is mediated by nuclear factor E2-related factor 2. Cancer Res. 2006;66:8293–8296.
   PubMed Web of Science ®Google Scholar
• Kensler TW, Egner PA, Agyeman AS, et al. Keap1–Nrf2 signaling: a target for cancer prevention by sulforaphane. Natural products in cancer prevention and therapy. Berlin: Springer; 2012. p. 163–177.
   Google Scholar
• Russo M, Spagnuolo C, Russo GL, et al. Nrf2 targeting by sulforaphane: a potential therapy for cancer treatment. Crit Rev Food Sci Nutr. 2016:00-00. DOI: 10.1080/10408398.2016.1259983
   PubMedGoogle Scholar
• Kassahun K, Davis M, Hu P, et al. Biotransformation of the naturally occurring isothiocyanate sulforaphane in the rat: identification of phase I metabolites and glutathione conjugates. Chem Res Toxicol. 1997;10:1228–1233.
   PubMed Web of Science ®Google Scholar
• Agyeman AS, Chaerkady R, Shaw PG, et al. Transcriptomic and proteomic profiling of KEAP1 disrupted and sulforaphane-treated human breast epithelial cells reveals common expression profiles. Breast Cancer Res Treat. 2012;132:175–187.
   PubMed Web of Science ®Google Scholar
• Kensler TW, Egner PA, Agyeman AS, et al. Keap1-nrf2 signaling: a target for cancer prevention by sulforaphane. Top Curr Chem. 2013;329:163–177.
   PubMed Web of Science ®Google Scholar
• Milczarek M, Misiewicz-Krzeminska I, Lubelska K, et al. Combination treatment with 5-fluorouracil and isothiocyanates shows an antagonistic effect in Chinese hamster fibroblast cells line-V79. Acta Pol Pharm. 2011;68:331–342.
   PubMed Web of Science ®Google Scholar
• Fimognari C, Nusse M, Lenzi M, et al. Sulforaphane increases the efficacy of doxorubicin in mouse fibroblasts characterized by p53 mutations. Mutat Res. 2006;601:92–101.
   PubMed Web of Science ®Google Scholar
• Qazi A, Pal J, Maitah M, et al. Anticancer activity of a broccoli derivative, sulforaphane, in barrett adenocarcinoma: potential use in chemoprevention and as adjuvant in chemotherapy. Transl Oncol. 2010;3:389–399.
   PubMed Web of Science ®Google Scholar
• Wang X, Doherty GP, Leith MK, et al. Enhanced cytotoxicity of mitomycin C in human tumour cells with inducers of DT-diaphorase. Br J Cancer. 1999;80:1223–1230.
   PubMed Web of Science ®Google Scholar
• Perez MJ, Gonzalez-Sanchez E, Gonzalez-Loyola A, et al. Mitochondrial genome depletion dysregulates bile acid- and paracetamol-induced expression of the transporters Mdr1, Mrp1 and Mrp4 in liver cells. Br J Pharmacol. 2011;162:1686–1699.
   PubMed Web of Science ®Google Scholar
• Ji L, Wei Y, Jiang T, et al. Correlation of Nrf2, NQO1, MRP1, cmyc and p53 in colorectal cancer and their relationships to clinicopathologic features and survival. Int J Clin Exp Pathol. 2014;7:1124–1131.
   PubMed Web of Science ®Google Scholar
• No JH, Kim YB, Song YS. Targeting nrf2 signaling to combat chemoresistance. J Cancer Prev. 2014;19:111–117.
   PubMedGoogle Scholar
• Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat Immunol. 2011;12:715–723.
   PubMed Web of Science ®Google Scholar
• Wakabayashi N, Slocum SL, Skoko JJ, et al. When NRF2 talks, who’s listening? Antioxid Redox Signal. 2010;13:1649–1663.
   PubMed Web of Science ®Google Scholar
• Brunelli D, Tavecchio M, Falcioni C, et al. The isothiocyanate produced from glucomoringin inhibits NF-kB and reduces myeloma growth in nude mice in vivo. Biochem Pharmacol. 2010;79:1141–1148.
   PubMed Web of Science ®Google Scholar
• Rushworth SA, Zaitseva L, Murray MY, et al. The high Nrf2 expression in human acute myeloid leukemia is driven by NF-kappaB and underlies its chemo-resistance. Blood. 2012;120:5188–5198.
   PubMed Web of Science ®Google Scholar
• Saldanha JF, Leal VO, Rizzetto F, et al. Effects of resveratrol supplementation in Nrf2 and NF-kappaB expressions in nondialyzed chronic kidney disease patients: a randomized, double-blind, placebo-controlled, crossover clinical trial. J Ren Nutr. 2016;26:401–406.
   PubMed Web of Science ®Google Scholar
• Wallerath T, Deckert G, Ternes T, et al. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation. 2002;106:1652–1658.
   PubMed Web of Science ®Google Scholar
• Marques FZ, Markus MA, Morris BJ. Resveratrol: cellular actions of a potent natural chemical that confers a diversity of health benefits. Int J Biochem Cell Biol. 2009;41:2125–2128.
   PubMed Web of Science ®Google Scholar
• Subramanian M, Goswami M, Chakraborty S, et al. Resveratrol induced inhibition of Escherichia coli proceeds via membrane oxidation and independent of diffusible reactive oxygen species generation. Redox Biol. 2014;2:865–872.
   PubMed Web of Science ®Google Scholar
• Menendez JA, Joven J, Aragones G, et al. Xenohormetic and anti-aging activity of secoiridoid polyphenols present in extra virgin olive oil: a new family of gerosuppressant agents. Cell Cycle. 2013;12:555–578.
   PubMed Web of Science ®Google Scholar
• Shen MY, Hsiao G, Liu CL, et al. Inhibitory mechanisms of resveratrol in platelet activation: pivotal roles of p38 MAPK and NO/cyclic GMP. Br J Haematol. 2007;139:475–485.
   PubMed Web of Science ®Google Scholar
• Shen C, Cheng W, Yu P, et al. Resveratrol pretreatment attenuates injury and promotes proliferation of neural stem cells following oxygen-glucose deprivation/reoxygenation by upregulating the expression of Nrf2, HO-1 and NQO1 in vitro. Mol Med Rep. 2016;14:3646–3654.
   PubMed Web of Science ®Google Scholar
• Rauf A, Imran M, Butt MS, et al. Resveratrol as an anticancer agent: a review. Crit Rev Food Sci Nutr. 2016;00-00. DOI:10.1080/10408398.2016.1263597
   PubMedGoogle Scholar
• Calabrese EJ, Mattson MP, Calabrese V. Resveratrol commonly displays hormesis: occurrence and biomedical significance. Hum Exp Toxicol. 2010;29:980–1015.
   PubMed Web of Science ®Google Scholar
• Plauth A, Geikowski A, Cichon S, et al. Hormetic shifting of redox environment by pro-oxidative resveratrol protects cells against stress. Free Radic Biol Med. 2016;99:608–622.
   PubMed Web of Science ®Google Scholar
• Rai G, Mishra S, Suman S, et al. Resveratrol improves the anticancer effects of doxorubicin in vitro and in vivo models: a mechanistic insight. Phytomedicine. 2016;23:233–242.
   PubMed Web of Science ®Google Scholar
• Lee YJ, Im JH, Lee DM, et al. Synergistic inhibition of mesothelioma cell growth by the combination of clofarabine and resveratrol involves Nrf2 downregulation. BMB Rep. 2012;45:647–652.
   PubMed Web of Science ®Google Scholar
• Lee YJ, Park IS, Lee YJ, et al. Resveratrol contributes to chemosensitivity of malignant mesothelioma cells with activation of p53. Food Chem Toxicol. 2014;63:153–160.
   PubMed Web of Science ®Google Scholar
• Li Y, Liu J, Liu X, et al. Resveratrol-induced cell inhibition of growth and apoptosis in MCF7 human breast cancer cells are associated with modulation of phosphorylated Akt and caspase-9. Appl Biochem Biotechnol. 2006;135:181–192.
   PubMed Web of Science ®Google Scholar
• Vyas S, Asmerom Y, De Leon DD. Resveratrol regulates insulin-like growth factor-II in breast cancer cells. Endocrinology. 2005;146:4224–4233.
   PubMed Web of Science ®Google Scholar
• Vyas S, Asmerom Y, De Leon DD. Insulin-like growth factor II mediates resveratrol stimulatory effect on cathepsin D in breast cancer cells. Growth Factors. 2006;24:79–87.
   PubMed Web of Science ®Google Scholar
• Wietzke JA, Welsh J. Phytoestrogen regulation of a Vitamin D3 receptor promoter and 1,25-dihydroxyvitamin D3 actions in human breast cancer cells. J Steroid Biochem Mol Biol. 2003;84:149–157.
   PubMed Web of Science ®Google Scholar
• George J, Singh M, Srivastava AK, et al. Resveratrol and black tea polyphenol combination synergistically suppress mouse skin tumors growth by inhibition of activated MAPKs and p53. PLoS One. 2011;6:e23395.
   PubMed Web of Science ®Google Scholar
• Roy P, Kalra N, Prasad S, et al. Chemopreventive potential of resveratrol in mouse skin tumors through regulation of mitochondrial and PI3K/AKT signaling pathways. Pharm Res. 2009;26:211–217.
   PubMed Web of Science ®Google Scholar
• Luo H, Wang L, Schulte BA, et al. Resveratrol enhances ionizing radiation-induced premature senescence in lung cancer cells. Int J Oncol. 2013;43:1999–2006.
   PubMed Web of Science ®Google Scholar
• Al-Abd AM, Mahmoud AM, El-Sherbiny GA, et al. Resveratrol enhances the cytotoxic profile of docetaxel and doxorubicin in solid tumour cell lines in vitro. Cell Prolif. 2011;44:591–601.
   PubMed Web of Science ®Google Scholar
• Kim TH, Shin YJ, Won AJ, et al. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin. Biochim Biophys Acta. 2014;1840:615–625.
   PubMed Web of Science ®Google Scholar
• Kuo MT. Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal. 2009;11:99–133.
   PubMed Web of Science ®Google Scholar
• Nessa MU, Beale P, Chan C, et al. Combinations of resveratrol, cisplatin and oxaliplatin applied to human ovarian cancer cells. Anticancer Res. 2012;32:53–59.
   PubMed Web of Science ®Google Scholar
• Ko JC, Syu JJ, Chen JC, et al. Resveratrol enhances etoposide-induced cytotoxicity through down-regulating ERK1/2 and AKT-mediated X-ray repair cross-complement group 1 (XRCC1) protein expression in human non-small-cell lung cancer cells. Basic Clin Pharmacol Toxicol. 2015;117:383–391.
   PubMed Web of Science ®Google Scholar
• Sun GB, Sun X, Wang M, et al. Oxidative stress suppression by luteolin-induced heme oxygenase-1 expression. Toxicol Appl Pharmacol. 2012;265:229–240.
   PubMed Web of Science ®Google Scholar
• Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009;9:400–414.
   PubMed Web of Science ®Google Scholar
• Lee YJ, Lee YJ, Im JH, et al. Synergistic anti-cancer effects of resveratrol and chemotherapeutic agent clofarabine against human malignant mesothelioma MSTO-211H cells. Food Chem Toxicol. 2013;52:61–68.
   PubMed Web of Science ®Google Scholar
• Lin CJ, Lee CC, Shih YL, et al. Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy. Free Radic Biol Med. 2012;52:377–391.
   PubMed Web of Science ®Google Scholar
• Singh B, Shoulson R, Chatterjee A, et al. Resveratrol inhibits estrogen-induced breast carcinogenesis through induction of NRF2-mediated protective pathways. Carcinogenesis. 2014;35:1872–1880.
   PubMed Web of Science ®Google Scholar
• Gatouillat G, Balasse E, Joseph-Pietras D, et al. Resveratrol induces cell-cycle disruption and apoptosis in chemoresistant B16 melanoma. J Cell Biochem. 2010;110:893–902.
   PubMed Web of Science ®Google Scholar
• Osman AM, Telity SA, Damanhouri ZA, et al. Chemosensitizing and nephroprotective effect of resveratrol in cisplatin -treated animals. Cancer Cell Int. 2015;15:6.
   PubMed Web of Science ®Google Scholar
• Mao QQ, Bai Y, Lin YW, et al. Resveratrol confers resistance against taxol via induction of cell cycle arrest in human cancer cell lines. Mol Nutr Food Res. 2010;54:1574–1584.
   PubMed Web of Science ®Google Scholar
• Niu XF, Liu BQ, Du ZX, et al. Resveratrol protects leukemic cells against cytotoxicity induced by proteasome inhibitors via induction of FOXO1 and p27Kip1. BMC Cancer. 2011;11:99.
   PubMed Web of Science ®Google Scholar
• Chen B, Cao H, Chen L, et al. Rifampicin attenuated global cerebral ischemia injury via activating the nuclear factor erythroid 2-related factor pathway. Front Cell Neurosci. 2016;10:273.
   PubMed Web of Science ®Google Scholar
• Li M, Liu X, He Y, et al. Celastrol attenuates angiotensin II mediated human umbilical vein endothelial cells damage through activation of Nrf2/ERK1/2/Nox2 signal pathway. Eur J Pharmacol. 2017;797:124–133.
   PubMed Web of Science ®Google Scholar
• Xu X, Li H, Hou X, et al. Punicalagin induces Nrf2/HO-1 expression via upregulation of PI3K/AKT pathway and inhibits LPS-induced oxidative stress in RAW264.7 macrophages. Mediators Inflamm. 2015;2015:380218.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Li Y, Ni HM, et al. Nrf2 but not autophagy inhibition is associated with the survival of wild-type epidermal growth factor receptor non-small cell lung cancer cells. Toxicol Appl Pharmacol. 2016;310:140–149.
   PubMed Web of Science ®Google Scholar
• Zhao M, Lau ST, Leung PS, et al. Seven quassinoids from Fructus Bruceae with cytotoxic effects on pancreatic adenocarcinoma cell lines. Phytother Res. 2011;25:1796–1800.
   PubMed Web of Science ®Google Scholar
• Wu T, Harder BG, Wong PK, et al. Oxidative stress, mammospheres and Nrf2-new implication for breast cancer therapy? Mol Carcinog. 2015;54:1494–1502.
   PubMed Web of Science ®Google Scholar
• Ren D, Villeneuve NF, Jiang T, et al. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc Natl Acad Sci U S A. 2011;108:1433–1438.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang Y, Zhang Z, et al. Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-AKR1C1 pathway. Oncotarget. 2016;7:10363–10372.
   PubMed Web of Science ®Google Scholar
• Harder B, Tian W, La Clair JJ, et al. Brusatol overcomes chemoresistance through inhibition of protein translation. Mol Carcinog. 2016. DOI:10.1002/mc.22609
   Web of Science ®Google Scholar
• Vartanian S, Ma TP, Lee J, et al. Application of mass spectrometry profiling to establish brusatol as an inhibitor of global protein synthesis. Mol Cell Proteomics. 2016;15:1220–1231.
   PubMed Web of Science ®Google Scholar
• Olayanju A, Copple IM, Bryan HK, et al. Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity-implications for therapeutic targeting of Nrf2. Free Radic Biol Med. 2015;78:202–212.
   PubMed Web of Science ®Google Scholar
• Tao S, Wang S, Moghaddam SJ, et al. Oncogenic KRAS confers chemoresistance by upregulating NRF2. Cancer Res. 2014;74:7430–7441.
   PubMed Web of Science ®Google Scholar
• Sun X, Wang Q, Wang Y, et al. Brusatol enhances the radiosensitivity of A549 cells by promoting ROS production and enhancing DNA damage. Int J Mol Sci. 2016;17.
   Web of Science ®Google Scholar
• Hall IH, Lee KH, Eigebaly SA, et al. Antitumor agents. XXXIV: mechanism of action of bruceoside A and brusatol on nucleic acid metabolism of P-388 lymphocytic leukemia cells. J Pharm Sci. 1979;68:883–887.
   PubMed Web of Science ®Google Scholar
• Tarumoto T, Nagai T, Ohmine K, et al. Ascorbic acid restores sensitivity to imatinib via suppression of Nrf2-dependent gene expression in the imatinib-resistant cell line. Exp Hematol. 2004;32:375–381.
   PubMed Web of Science ®Google Scholar
• Xu X, Zhang X, Zhang Y, et al. Wogonin reversed resistant human myelogenous leukemia cells via inhibiting Nrf2 signaling by Stat3/NF-kappaB inactivation. Sci Rep. 2017;7:39950.
   PubMed Web of Science ®Google Scholar
• Arlt A, Sebens S, Krebs S, et al. Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity. Oncogene. 2013;32:4825–4835.
   PubMed Web of Science ®Google Scholar
• Kim EH, Jang H, Shin D, et al. Targeting Nrf2 with wogonin overcomes cisplatin resistance in head and neck cancer. Apoptosis. 2016;21:1265–1278.
   PubMed Web of Science ®Google Scholar
• Roh JL, Kim EH, Jang H, et al. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis. Redox Biol. 2017;11:254–262.
   PubMed Web of Science ®Google Scholar
• Chian S, Thapa R, Chi Z, et al. Luteolin inhibits the Nrf2 signaling pathway and tumor growth in vivo. Biochem Biophys Res Commun. 2014;447:602–608.
   PubMed Web of Science ®Google Scholar
• Lin JK. Molecular targets of curcumin. Adv Exp Med Biol. 2007;595:227–243.
   PubMed Web of Science ®Google Scholar
• Rai D, Singh JK, Roy N, et al. Curcumin inhibits FtsZ assembly: an attractive mechanism for its antibacterial activity. Biochem J. 2008;410:147–155.
   PubMed Web of Science ®Google Scholar
• Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003;23:363–398.
   PubMed Web of Science ®Google Scholar
• Hill-Kapturczak N, Thamilselvan V, Liu F, et al. Mechanism of heme oxygenase-1 gene induction by curcumin in human renal proximal tubule cells. Am J Physiol Renal Physiol. 2001;281:F851–859.
   PubMed Web of Science ®Google Scholar
• Motterlini R, Foresti R, Bassi R, et al. Curcumin, an antioxidant and anti-inflammatory agent, induces heme oxygenase-1 and protects endothelial cells against oxidative stress. Free Radic Biol Med. 2000;28:1303–1312.
   PubMed Web of Science ®Google Scholar
• Scapagnini G, Foresti R, Calabrese V, et al. Caffeic acid phenethyl ester and curcumin: a novel class of heme oxygenase-1 inducers. Mol Pharmacol. 2002;61:554–561.
   PubMed Web of Science ®Google Scholar
• Jones EA, Shahed A, Shoskes DA. Modulation of apoptotic and inflammatory genes by bioflavonoids and angiotensin II inhibition in ureteral obstruction. Urology. 2000;56:346–351.
   PubMed Web of Science ®Google Scholar
• Andreadi CK, Howells LM, Atherfold PA, et al. Involvement of Nrf2, p38, B-Raf, and nuclear factor-kappaB, but not phosphatidylinositol 3-kinase, in induction of hemeoxygenase-1 by dietary polyphenols. Mol Pharmacol. 2006;69:1033–1040.
   PubMed Web of Science ®Google Scholar
• Balogun E, Hoque M, Gong P, et al. Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. Biochem J. 2003;371:887–895.
   PubMed Web of Science ®Google Scholar
• Farombi EO, Shrotriya S, Na HK, et al. Curcumin attenuates dimethylnitrosamine-induced liver injury in rats through Nrf2-mediated induction of heme oxygenase-1. Food Chem Toxicol. 2008;46:1279–1287.
   PubMed Web of Science ®Google Scholar
• Anand P, Kunnumakkara AB, Newman RA, et al. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4:807–818.
   PubMed Web of Science ®Google Scholar
• Khor TO, Huang Y, Wu TY, et al. Pharmacodynamics of curcumin as DNA hypomethylation agent in restoring the expression of Nrf2 via promoter CpGs demethylation. Biochem Pharmacol. 2011;82:1073–1078.
   PubMed Web of Science ®Google Scholar
• Teiten MH, Dicato M, Diederich M. Curcumin as a regulator of epigenetic events. Mol Nutr Food Res. 2013;57:1619–1629.
   PubMed Web of Science ®Google Scholar
• Shu L, Khor TO, Lee JH, et al. Epigenetic CpG demethylation of the promoter and reactivation of the expression of Neurog1 by curcumin in prostate LNCaP cells. Aaps J. 2011;13:606–614.
   PubMed Web of Science ®Google Scholar
• Kamat AM, Sethi G, Aggarwal BB. Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-kappaB and nuclear factor-kappaB-regulated gene products in IFN-alpha-sensitive and IFN-alpha-resistant human bladder cancer cells. Mol Cancer Ther. 2007;6:1022–1030.
   PubMed Web of Science ®Google Scholar
• Hartojo W, Silvers AL, Thomas DG, et al. Curcumin promotes apoptosis, increases chemosensitivity, and inhibits nuclear factor kappaB in esophageal adenocarcinoma. Transl Oncol. 2010;3:99–108.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay A, Bueso-Ramos C, Chatterjee D, et al. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene. 2001;20:7597–7609.
   PubMed Web of Science ®Google Scholar
• Weir NM, Selvendiran K, Kutala VK, et al. Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK. Cancer Biol Ther. 2007;6:178–184.
   PubMed Web of Science ®Google Scholar
• Kang KA, Hyun JW. Oxidative stress, Nrf2, and epigenetic modification contribute to anticancer drug resistance. Toxicol Res. 2017;33:1–5.
   PubMedGoogle Scholar
• Motohashi H, O’Connor T, Katsuoka F, et al. Integration and diversity of the regulatory network composed of Maf and CNC families of transcription factors. Gene. 2002;294:1–12.
   PubMed Web of Science ®Google Scholar
• Kannan MB, Solovieva V, Blank V. The small MAF transcription factors MAFF, MAFG and MAFK: current knowledge and perspectives. Biochim Biophys Acta. 2012;1823:1841–1846.
   PubMed Web of Science ®Google Scholar
• Lopez-Perez R, Gutierrez N, Isidro I, et al. Absence of differences in the gene expression profiling of a childhood ALL time-space cluster. Blood. 2003;102:234B–235B. Washington: Amer Soc Hematology.
   Google Scholar
• Geismann C, Arlt A, Sebens S, et al. Cytoprotection “gone astray”: Nrf2 and its role in cancer. Onco Targets Ther. 2014;7:1497–1518.
   PubMed Web of Science ®Google Scholar